Maynard Um
-
-
-
-
-
-
-
Skye Bioscience (SKYE) Misses Q3 EPS by 32c
-
-
-
-
-
-
-
Skye Bioscience reports preclinical obesity drug data ahead of phase 2
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Skye Bioscience (SKYE)
-
-
-
-
-
-
-
Skye Bioscience (SKYE) Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
-
-
-
-
-
-
-
Skye Bioscience (SKYE) Appoints Puneet S. Arora as Chief Medical Officer
-
-
-
-
-
-
-
Craig-Hallum Starts Skye Bioscience (SKYE) at Buy
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

